Arthritis & Rheumatism, Volume 65,
October 2013 Abstract Supplement

Abstracts of the 2013 American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Meeting
San Diego, CA October 25-30, 2013.


Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea.

Sung,  Yoon-Kyoung, Yoshida,  Kazuki, Prince,  Femke H.M., Frits,  Michelle A., Choe,  Jung-Yoon, Chung,  Won Tae, Lee,  Jisoo

1Brigham and Women's Hospital, Boston, MA
2Catholic University of Daegu School of Medicine, Daegu, South Korea
3Dong-A University Hospital, Busan, South Korea
4Ewha Womans University Mokdong Hospital, Seoul, South Korea
5Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
6Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Background/Purpose:

Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries, it is valuable to compare QOL measures across countries. The objective of this study was to compare health-related quality of life (HRQOL) of rheumatoid arthritis (RA) patients between United States (US) and South Korea.

Methods:

Two year follow-up data on health and HRQOL measured with EuroQoL-5 dimension (EQ-5D) between 2009 and 2011 were compared between US-based (BRASS) and Korean-based (KORONA) cohorts. A total of 1,166 subjects (187 from BRASS and 979 from KORONA) were included in this study to compare the cross-sectional differences in QOL in 2009 and the longitudinal two-year change through 2011. We performed multivariate linear regression analyses to identify factors associated with QOL and its changes in each cohort.

Results:

The mean (standard deviation) of EQ-5D score (1.0 being the best possible score) of BRASS subjects was 0.82 (0.16) and that of KORONA subjects was 0.69 (0.25) (P <0.01) at baseline in 2009 (see table). Disease activity score (DAS) 28 (P<0.01) and modified health assessment questionnaire (MHAQ) score (P<0.01) were inversely associated high QOL in both cohorts. Income level (P<0.01) was positively and the number of comorbidities (P<0.01) was negatively associated with QOL only in KORONA (see table). Mean changes in QOL were not different between cohorts (P=0.17). Only changes in DAS28 and MHAQ during 2 years were significantly associated with the change in QOL in both cohorts.

Table. Multivariate linear regression analyses of predictors for utility score in 2009 and change until 2011

  EQ-5D in 2009  ΔEQ-5D between 2009 and 2011 
Cohort  BRASS (161)    KORONA (947)    BRASS (159)    KORONA (934)   
R2 (adjusted R2)  0.57 (0.53)    0.59 (0.58)    0.27 (0.21)    0.28 (0.27)   
  B (95% CI)  B (95% CI)  B (95% CI)  B (95% CI) 
Intercept 0.77 (0.63∼0.92) <0.01 0.96 (0.85∼1.07) <0.01 0.11 (−0.07∼0.30) 0.23 −0.12 (−0.25∼0.02) 0.10
Age 0.001 (−0.001∼0.003) 0.30 −0.0001 (−0.001∼0.001) 0.83 −0.0009 (−0.003∼0.001) 0.43 0.001 0.17
Disease duration 0.001 (−0.001∼0.003) 0.22 0.0002 (−0.001∼0.002) 0.79 0.0002 (−0.002∼0.003) 0.88 0.001 0.46
Income 0.02 (−0.002∼0.04) 0.07 0.03 (0.01∼0.05) <0.01 0.003 (−0.02∼0.03) 0.80 −0.01 (−0.04∼0.01) 0.28
Education 0.03 (−0.01∼0.07) 0.09 −0.02 (−0.05∼0.01) 0.19 −0.04 (−0.09∼0.01) 0.13 0.03 (0∼0.07) 0.07
Number of comorbidity 0.01 (−0.01∼0.04) 0.32 −0.02 (−0.04∼−0.01) 0.01 −0.02 (−0.05∼0.02) 0.35 0.01 (−0.01∼0.08) 0.54
Female −0.01 (−0.05∼0.04) 0.80 −0.03 (−0.06∼0.002) 0.06 −0.01 (−0.07∼0.04) 0.62 0.002 (−0.04∼0.04) 0.93
Rheumatoid Factor 0.02 (−0.02∼0.06) 0.28 0.01 (−0.03∼0.04) 0.68 0.01 (−0.04∼0.06) 0.68 0.03 (−0.01∼0.08) 0.17
Biologic DMARD 0.03 (−0.004∼0.07) 0.08 0.004 (−0.04∼0.04) 0.85 −0.01 (−0.06∼0.03) 0.63 −0.04 (−0.09∼0.02) 0.17
NSAID −0.02 (−0.05∼0.02) 0.30 −0.004 (−0.03∼0.02) 0.72 0.03 (−0.02∼0.07) 0.21 0.02 (−0.01∼0.04) 0.27
Steroid −0.004 (−0.04∼0.05) 0.86 −0.01 (−0.03∼0.02) 0.50 −0.04 (−0.10∼0.02) 0.17 −0.01 (−0.04∼0.02) 0.58
DAS28-CRP −0.04 (−0.05∼−0.03) <0.01 −0.05 (−0.06∼−0.03) <0.01
Modified HAQ −0.18 (−0.24∼−0.13) <0.01 −0.35 (−0.38∼−0.32) <0.01
Δ DAS28-CRP −0.03 (−0.04∼−0.01) <0.01 −0.04 (−0.05∼−0.03) <0.01
Δ Modified HAQ −0.17 (−0.23∼−0.10) <0.01 −0.28 (−0.31∼−0.24) <0.01
*P<0.05; BRASS, Brigham Rheumatoid Arthritis Sequential Study; KORONA, KORean Observational study Network for Arthritis; OR, odds ratio; CI, 95% confidence interval; HAQ, health assessment questionnaire

Conclusion:

In this cross-national comparison study, changes in QOL and predictors for QOL were comparable between US-based BRASS and Korean-based KORONA, in spite of the differences in baseline characteristics and QOL level in each population.

Disclosure: Y. K. Sung, None; K. Yoshida, None; F. H. M. Prince, None; M. A. Frits, None; J. Y. Choe, None; W. T. Chung, None; J. Lee, None; E. M. Koh, None; D. H. Yoo, None; S. M. Helfgott, Abbott Laboratories, 5, Genentech and Biogen IDEC Inc., 5; N. A. Shadick, None; M. E. Weinblatt, MedImmune, 2, Crescendo Bioscience, Inc., 2, Bristol Myers Squibb, 2, MedImmune, 5, Crescendo Bioscience, Inc., 5, Bristol Myers Squibb, 5; S. C. Bae, Regublic of Korea, 2, Abbott Immunology Pharmaceuticals, 2, Bristol-Myers Squibb, 2, Eisai, 2, GlaxoSmithKline, 2, MSD, 2, Pfizer Inc, 2; D. H. Solomon, Eli Lilly and Company, 2, Amgen, 2, Corrona, 2, UpToDate, 7, Pfizer Inc, 9, Novartis Pharmaceutical Corporation, 9.

To cite this abstract, please use the following information:
Sung, Yoon-Kyoung, Yoshida, Kazuki, Prince, Femke H.M., Frits, Michelle A., Choe, Jung-Yoon, Chung, Won Tae, et al; Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea. [abstract]. Arthritis Rheum 2013;65 Suppl 10 :1029
DOI: 10.1002/art.2013.65.issue-s10

Abstract Supplement

Meeting Menu

2013 ACR/ARHP